RNA Interference Therapy Proposes 'Vaccine-like' Approach for Hypertension Management
A new approach to managing hypertension is being explored through the use of long-acting RNA interference (RNAi) therapy. This method involves the use of small interfering RNA (siRNA) to target hepatic angiotensinogen, a key component in the renin-angiotensin-aldosterone system (RAAS), which plays a significant role in blood pressure regulation. The therapy, known as Zilebesiran, has shown promise in reducing systolic blood pressure for months following a single subcutaneous dose. This approach shifts the management of hypertension from daily medication adherence to a more scheduled, appointment-based system, similar to vaccine administration. The KARDIA-1 study demonstrated that dosing every three to six months could provide durable blood pressure control, reducing the reliance on daily patient compliance. 
